MD, PhD, FRCP, FACC, FESC
Professor Cleland was appointed the Director of the Robertson Centre for Biostatistics and Clinical Trials in 2016, an internationally accredited Clinical Trials Unit offering a complete service both to academic clinicians and industry. The special area of expertise is cardiovascular disease but includes all branches of medicine and social sciences.
He qualified from the University of Glasgow and completed his training at St. Mary’s, Paddington and Hammersmith Hospitals, London in 1989. In 1994, he was awarded a Senior Fellowship by the British Heart Foundation, moving back to Glasgow. He was appointed Professor of Cardiology at the University of Hull in 1999 and subsequently, in 2013, at the National Heart & Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College London, where he retains a part-time contract.
His main area of interest is in heart failure, extending from its epidemiology and prevention, to Phase II-IV randomized trials through to the development and implementation of guidelines. Particular
current interests include the influence of myocardial substrate on therapeutic response, congestion and inflammation as novel therapeutic targets, telemonitoring and theranostics.
He is a Past Chairman of the ESC Working Group on Heart Failure and of the British Society for Heart Failure, founded the European Journal of Heart Failure and chairs the Academic Committee of the National Heart Failure Audit and the National Clinical Specialties Research group on Heart Failure. He has published more than 800 papers in peer reviewed journals and is a Thomson Reuters Highly Cited Researcher.